Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor.
Identifieur interne : 001810 ( Ncbi/Curation ); précédent : 001809; suivant : 001811Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor.
Auteurs : Deepak Mittal ; Arabella Young ; Kimberley Stannard ; Michelle Yong ; Michele W L. Teng ; Bertrand Allard [Canada] ; John Stagg [Canada] ; Mark J. Smyth [Australie]Source :
- Cancer research [ 1538-7445 ] ; 2014.
English descriptors
- KwdEn :
- Adenosine A2 Receptor Antagonists (administration & dosage), Adenosine A2 Receptor Antagonists (pharmacology), Animals, Antibodies, Blocking (administration & dosage), Antibodies, Blocking (pharmacology), Antibodies, Monoclonal (administration & dosage), Antibodies, Monoclonal (pharmacology), Antineoplastic Agents (administration & dosage), Antineoplastic Agents (pharmacology), CD8-Positive T-Lymphocytes (immunology), Cell Line, Tumor, Disease Models, Animal, Female, Killer Cells, Natural (immunology), Lung Neoplasms (immunology), Lung Neoplasms (metabolism), Lung Neoplasms (secondary), Melanoma, Experimental, Mice, Neoplasm Metastasis, Neoplasms (drug therapy), Neoplasms (immunology), Neoplasms (metabolism), Neoplasms (mortality), Neoplasms (pathology), Programmed Cell Death 1 Receptor (antagonists & inhibitors), Programmed Cell Death 1 Receptor (metabolism), Receptor, Adenosine A2A (metabolism).
- MESH :
- chemical , administration & dosage : Adenosine A2 Receptor Antagonists, Antibodies, Blocking, Antibodies, Monoclonal, Antineoplastic Agents.
- chemical , antagonists & inhibitors : Programmed Cell Death 1 Receptor.
- chemical , metabolism : Programmed Cell Death 1 Receptor, Receptor, Adenosine A2A.
- chemical , pharmacology : Adenosine A2 Receptor Antagonists, Antibodies, Blocking, Antibodies, Monoclonal, Antineoplastic Agents.
- drug therapy : Neoplasms.
- immunology : CD8-Positive T-Lymphocytes, Killer Cells, Natural, Lung Neoplasms, Neoplasms.
- metabolism : Lung Neoplasms, Neoplasms.
- mortality : Neoplasms.
- pathology : Neoplasms.
- secondary : Lung Neoplasms.
- Animals, Cell Line, Tumor, Disease Models, Animal, Female, Melanoma, Experimental, Mice, Neoplasm Metastasis.
Abstract
Adenosine targeting is an attractive new approach to cancer treatment, but no clinical study has yet examined adenosine inhibition in oncology despite the safe clinical profile of adenosine A2A receptor inhibitors (A2ARi) in Parkinson disease. Metastasis is the main cause of cancer-related deaths worldwide, and therefore we have studied experimental and spontaneous mouse models of melanoma and breast cancer metastasis to demonstrate the efficacy and mechanism of a combination of A2ARi in combination with anti-PD-1 monoclonal antibody (mAb). This combination significantly reduces metastatic burden and prolongs the life of mice compared with either monotherapy alone. Importantly, the combination was only effective when the tumor expressed high levels of CD73, suggesting a tumor biomarker that at a minimum could be used to stratify patients that might receive this combination. The mechanism of the combination therapy was critically dependent on NK cells and IFNγ, and to a lesser extent, CD8(+) T cells and the effector molecule, perforin. Overall, these results provide a strong rationale to use A2ARi with anti-PD-1 mAb for the treatment of minimal residual and metastatic disease.
DOI: 10.1158/0008-5472.CAN-14-0957
PubMed: 24986517
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000715
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :000715
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000715
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :001810
Links to Exploration step
pubmed:24986517Curation
No country items
Deepak Mittal<affiliation><nlm:affiliation>Authors' Affiliations: Immunology in Cancer and Infection Laboratory and Cancer Immunoregulation and Immunotherapy Laboratories, QIMR Berghofer Medical Research Institute, Herston; School of Medicine, University of Queensland, Queensland, Australia; and.</nlm:affiliation><wicri:noCountry code="subField">Australia; and</wicri:noCountry></affiliation><affiliation><nlm:affiliation>Authors' Affiliations: Immunology in Cancer and Infection Laboratory and Cancer Immunoregulation and Immunotherapy Laboratories, QIMR Berghofer Medical Research Institute, Herston; School of Medicine, University of Queensland, Queensland, Australia; and.</nlm:affiliation><wicri:noCountry code="subField">Australia; and</wicri:noCountry></affiliation><affiliation><nlm:affiliation>Authors' Affiliations: Immunology in Cancer and Infection Laboratory and Cancer Immunoregulation and Immunotherapy Laboratories, QIMR Berghofer Medical Research Institute, Herston;</nlm:affiliation><wicri:noCountry code="subField">Herston</wicri:noCountry></affiliation><affiliation><nlm:affiliation>Authors' Affiliations: Immunology in Cancer and Infection Laboratory and Cancer Immunoregulation and Immunotherapy Laboratories, QIMR Berghofer Medical Research Institute, Herston;</nlm:affiliation><wicri:noCountry code="subField">Herston</wicri:noCountry></affiliation><affiliation><nlm:affiliation>Authors' Affiliations: Immunology in Cancer and Infection Laboratory and Cancer Immunoregulation and Immunotherapy Laboratories, QIMR Berghofer Medical Research Institute, Herston; School of Medicine, University of Queensland, Queensland, Australia; and.</nlm:affiliation><wicri:noCountry code="subField">Australia; and</wicri:noCountry></affiliation>Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor.</title><author><name sortKey="Mittal, Deepak" sort="Mittal, Deepak" uniqKey="Mittal D" first="Deepak" last="Mittal">Deepak Mittal</name><affiliation><nlm:affiliation>Authors' Affiliations: Immunology in Cancer and Infection Laboratory and Cancer Immunoregulation and Immunotherapy Laboratories, QIMR Berghofer Medical Research Institute, Herston; School of Medicine, University of Queensland, Queensland, Australia; and.</nlm:affiliation><wicri:noCountry code="subField">Australia; and</wicri:noCountry></affiliation></author><author><name sortKey="Young, Arabella" sort="Young, Arabella" uniqKey="Young A" first="Arabella" last="Young">Arabella Young</name><affiliation><nlm:affiliation>Authors' Affiliations: Immunology in Cancer and Infection Laboratory and Cancer Immunoregulation and Immunotherapy Laboratories, QIMR Berghofer Medical Research Institute, Herston; School of Medicine, University of Queensland, Queensland, Australia; and.</nlm:affiliation><wicri:noCountry code="subField">Australia; and</wicri:noCountry></affiliation></author><author><name sortKey="Stannard, Kimberley" sort="Stannard, Kimberley" uniqKey="Stannard K" first="Kimberley" last="Stannard">Kimberley Stannard</name><affiliation><nlm:affiliation>Authors' Affiliations: Immunology in Cancer and Infection Laboratory and Cancer Immunoregulation and Immunotherapy Laboratories, QIMR Berghofer Medical Research Institute, Herston;</nlm:affiliation><wicri:noCountry code="subField">Herston</wicri:noCountry></affiliation></author><author><name sortKey="Yong, Michelle" sort="Yong, Michelle" uniqKey="Yong M" first="Michelle" last="Yong">Michelle Yong</name><affiliation><nlm:affiliation>Authors' Affiliations: Immunology in Cancer and Infection Laboratory and Cancer Immunoregulation and Immunotherapy Laboratories, QIMR Berghofer Medical Research Institute, Herston;</nlm:affiliation><wicri:noCountry code="subField">Herston</wicri:noCountry></affiliation></author><author><name sortKey="Teng, Michele W L" sort="Teng, Michele W L" uniqKey="Teng M" first="Michele W L" last="Teng">Michele W L. Teng</name><affiliation><nlm:affiliation>Authors' Affiliations: Immunology in Cancer and Infection Laboratory and Cancer Immunoregulation and Immunotherapy Laboratories, QIMR Berghofer Medical Research Institute, Herston; School of Medicine, University of Queensland, Queensland, Australia; and.</nlm:affiliation><wicri:noCountry code="subField">Australia; and</wicri:noCountry></affiliation></author><author><name sortKey="Allard, Bertrand" sort="Allard, Bertrand" uniqKey="Allard B" first="Bertrand" last="Allard">Bertrand Allard</name><affiliation wicri:level="1"><nlm:affiliation>Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Faculté de Pharmacie et Institut du Cancer de Montréal, Montréal, Québec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Faculté de Pharmacie et Institut du Cancer de Montréal, Montréal, Québec</wicri:regionArea><wicri:noRegion>Québec</wicri:noRegion></affiliation></author><author><name sortKey="Stagg, John" sort="Stagg, John" uniqKey="Stagg J" first="John" last="Stagg">John Stagg</name><affiliation wicri:level="1"><nlm:affiliation>Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Faculté de Pharmacie et Institut du Cancer de Montréal, Montréal, Québec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Faculté de Pharmacie et Institut du Cancer de Montréal, Montréal, Québec</wicri:regionArea><wicri:noRegion>Québec</wicri:noRegion></affiliation></author><author><name sortKey="Smyth, Mark J" sort="Smyth, Mark J" uniqKey="Smyth M" first="Mark J" last="Smyth">Mark J. Smyth</name><affiliation wicri:level="1"><nlm:affiliation>Authors' Affiliations: Immunology in Cancer and Infection Laboratory and Cancer Immunoregulation and Immunotherapy Laboratories, QIMR Berghofer Medical Research Institute, Herston; School of Medicine, University of Queensland, Queensland, Australia; and mark.smyth@qimrberghofer.edu.au.</nlm:affiliation><country wicri:rule="url">Australie</country><wicri:regionArea>Authors' Affiliations: Immunology in Cancer and Infection Laboratory and Cancer Immunoregulation and Immunotherapy Laboratories, QIMR Berghofer Medical Research Institute, Herston; School of Medicine, University of Queensland, Queensland</wicri:regionArea><wicri:noRegion>Queensland</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24986517</idno><idno type="pmid">24986517</idno><idno type="doi">10.1158/0008-5472.CAN-14-0957</idno><idno type="wicri:Area/PubMed/Corpus">000715</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000715</idno><idno type="wicri:Area/PubMed/Curation">000715</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000715</idno><idno type="wicri:Area/PubMed/Checkpoint">000715</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000715</idno><idno type="wicri:Area/Ncbi/Merge">001810</idno><idno type="wicri:Area/Ncbi/Curation">001810</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor.</title><author><name sortKey="Mittal, Deepak" sort="Mittal, Deepak" uniqKey="Mittal D" first="Deepak" last="Mittal">Deepak Mittal</name><affiliation><nlm:affiliation>Authors' Affiliations: Immunology in Cancer and Infection Laboratory and Cancer Immunoregulation and Immunotherapy Laboratories, QIMR Berghofer Medical Research Institute, Herston; School of Medicine, University of Queensland, Queensland, Australia; and.</nlm:affiliation><wicri:noCountry code="subField">Australia; and</wicri:noCountry></affiliation></author><author><name sortKey="Young, Arabella" sort="Young, Arabella" uniqKey="Young A" first="Arabella" last="Young">Arabella Young</name><affiliation><nlm:affiliation>Authors' Affiliations: Immunology in Cancer and Infection Laboratory and Cancer Immunoregulation and Immunotherapy Laboratories, QIMR Berghofer Medical Research Institute, Herston; School of Medicine, University of Queensland, Queensland, Australia; and.</nlm:affiliation><wicri:noCountry code="subField">Australia; and</wicri:noCountry></affiliation></author><author><name sortKey="Stannard, Kimberley" sort="Stannard, Kimberley" uniqKey="Stannard K" first="Kimberley" last="Stannard">Kimberley Stannard</name><affiliation><nlm:affiliation>Authors' Affiliations: Immunology in Cancer and Infection Laboratory and Cancer Immunoregulation and Immunotherapy Laboratories, QIMR Berghofer Medical Research Institute, Herston;</nlm:affiliation><wicri:noCountry code="subField">Herston</wicri:noCountry></affiliation></author><author><name sortKey="Yong, Michelle" sort="Yong, Michelle" uniqKey="Yong M" first="Michelle" last="Yong">Michelle Yong</name><affiliation><nlm:affiliation>Authors' Affiliations: Immunology in Cancer and Infection Laboratory and Cancer Immunoregulation and Immunotherapy Laboratories, QIMR Berghofer Medical Research Institute, Herston;</nlm:affiliation><wicri:noCountry code="subField">Herston</wicri:noCountry></affiliation></author><author><name sortKey="Teng, Michele W L" sort="Teng, Michele W L" uniqKey="Teng M" first="Michele W L" last="Teng">Michele W L. Teng</name><affiliation><nlm:affiliation>Authors' Affiliations: Immunology in Cancer and Infection Laboratory and Cancer Immunoregulation and Immunotherapy Laboratories, QIMR Berghofer Medical Research Institute, Herston; School of Medicine, University of Queensland, Queensland, Australia; and.</nlm:affiliation><wicri:noCountry code="subField">Australia; and</wicri:noCountry></affiliation></author><author><name sortKey="Allard, Bertrand" sort="Allard, Bertrand" uniqKey="Allard B" first="Bertrand" last="Allard">Bertrand Allard</name><affiliation wicri:level="1"><nlm:affiliation>Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Faculté de Pharmacie et Institut du Cancer de Montréal, Montréal, Québec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Faculté de Pharmacie et Institut du Cancer de Montréal, Montréal, Québec</wicri:regionArea><wicri:noRegion>Québec</wicri:noRegion></affiliation></author><author><name sortKey="Stagg, John" sort="Stagg, John" uniqKey="Stagg J" first="John" last="Stagg">John Stagg</name><affiliation wicri:level="1"><nlm:affiliation>Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Faculté de Pharmacie et Institut du Cancer de Montréal, Montréal, Québec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Faculté de Pharmacie et Institut du Cancer de Montréal, Montréal, Québec</wicri:regionArea><wicri:noRegion>Québec</wicri:noRegion></affiliation></author><author><name sortKey="Smyth, Mark J" sort="Smyth, Mark J" uniqKey="Smyth M" first="Mark J" last="Smyth">Mark J. Smyth</name><affiliation wicri:level="1"><nlm:affiliation>Authors' Affiliations: Immunology in Cancer and Infection Laboratory and Cancer Immunoregulation and Immunotherapy Laboratories, QIMR Berghofer Medical Research Institute, Herston; School of Medicine, University of Queensland, Queensland, Australia; and mark.smyth@qimrberghofer.edu.au.</nlm:affiliation><country wicri:rule="url">Australie</country><wicri:regionArea>Authors' Affiliations: Immunology in Cancer and Infection Laboratory and Cancer Immunoregulation and Immunotherapy Laboratories, QIMR Berghofer Medical Research Institute, Herston; School of Medicine, University of Queensland, Queensland</wicri:regionArea><wicri:noRegion>Queensland</wicri:noRegion></affiliation></author></analytic><series><title level="j">Cancer research</title><idno type="eISSN">1538-7445</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenosine A2 Receptor Antagonists (administration & dosage)</term><term>Adenosine A2 Receptor Antagonists (pharmacology)</term><term>Animals</term><term>Antibodies, Blocking (administration & dosage)</term><term>Antibodies, Blocking (pharmacology)</term><term>Antibodies, Monoclonal (administration & dosage)</term><term>Antibodies, Monoclonal (pharmacology)</term><term>Antineoplastic Agents (administration & dosage)</term><term>Antineoplastic Agents (pharmacology)</term><term>CD8-Positive T-Lymphocytes (immunology)</term><term>Cell Line, Tumor</term><term>Disease Models, Animal</term><term>Female</term><term>Killer Cells, Natural (immunology)</term><term>Lung Neoplasms (immunology)</term><term>Lung Neoplasms (metabolism)</term><term>Lung Neoplasms (secondary)</term><term>Melanoma, Experimental</term><term>Mice</term><term>Neoplasm Metastasis</term><term>Neoplasms (drug therapy)</term><term>Neoplasms (immunology)</term><term>Neoplasms (metabolism)</term><term>Neoplasms (mortality)</term><term>Neoplasms (pathology)</term><term>Programmed Cell Death 1 Receptor (antagonists & inhibitors)</term><term>Programmed Cell Death 1 Receptor (metabolism)</term><term>Receptor, Adenosine A2A (metabolism)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Adenosine A2 Receptor Antagonists</term><term>Antibodies, Blocking</term><term>Antibodies, Monoclonal</term><term>Antineoplastic Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Programmed Cell Death 1 Receptor</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Programmed Cell Death 1 Receptor</term><term>Receptor, Adenosine A2A</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Adenosine A2 Receptor Antagonists</term><term>Antibodies, Blocking</term><term>Antibodies, Monoclonal</term><term>Antineoplastic Agents</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Neoplasms</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>CD8-Positive T-Lymphocytes</term><term>Killer Cells, Natural</term><term>Lung Neoplasms</term><term>Neoplasms</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Lung Neoplasms</term><term>Neoplasms</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Neoplasms</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Neoplasms</term></keywords><keywords scheme="MESH" qualifier="secondary" xml:lang="en"><term>Lung Neoplasms</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Cell Line, Tumor</term><term>Disease Models, Animal</term><term>Female</term><term>Melanoma, Experimental</term><term>Mice</term><term>Neoplasm Metastasis</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Adenosine targeting is an attractive new approach to cancer treatment, but no clinical study has yet examined adenosine inhibition in oncology despite the safe clinical profile of adenosine A2A receptor inhibitors (A2ARi) in Parkinson disease. Metastasis is the main cause of cancer-related deaths worldwide, and therefore we have studied experimental and spontaneous mouse models of melanoma and breast cancer metastasis to demonstrate the efficacy and mechanism of a combination of A2ARi in combination with anti-PD-1 monoclonal antibody (mAb). This combination significantly reduces metastatic burden and prolongs the life of mice compared with either monotherapy alone. Importantly, the combination was only effective when the tumor expressed high levels of CD73, suggesting a tumor biomarker that at a minimum could be used to stratify patients that might receive this combination. The mechanism of the combination therapy was critically dependent on NK cells and IFNγ, and to a lesser extent, CD8(+) T cells and the effector molecule, perforin. Overall, these results provide a strong rationale to use A2ARi with anti-PD-1 mAb for the treatment of minimal residual and metastatic disease.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001810 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 001810 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Ncbi
|étape= Curation
|type= RBID
|clé= pubmed:24986517
|texte= Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:24986517" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |